{"name":"USWM, LLC (dba US WorldMeds)","slug":"uswm-llc-dba-us-worldmeds","ticker":"","exchange":"","domain":"uswmllcdbausworldmeds.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Open Label Lofexidine HCL","genericName":"Open Label Lofexidine HCL","slug":"open-label-lofexidine-hcl","indication":"Opioid withdrawal syndrome","status":"phase_3"},{"name":"lofexidine HCl","genericName":"lofexidine HCl","slug":"lofexidine-hcl","indication":"Opioid withdrawal","status":"marketed"}]}],"pipeline":[{"name":"Open Label Lofexidine HCL","genericName":"Open Label Lofexidine HCL","slug":"open-label-lofexidine-hcl","phase":"phase_3","mechanism":"Lofexidine is an alpha-2 adrenergic agonist that reduces noradrenergic hyperactivity associated with opioid withdrawal.","indications":["Opioid withdrawal syndrome"],"catalyst":""},{"name":"lofexidine HCl","genericName":"lofexidine HCl","slug":"lofexidine-hcl","phase":"marketed","mechanism":"Lofexidine is an alpha-2 adrenergic agonist that reduces noradrenergic hyperactivity in the central nervous system to alleviate opioid withdrawal symptoms.","indications":["Opioid withdrawal"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOelhDNW5zVWpGbERpT1Z6VEk2Wk1TQjU1NmFaLUt6aTFUblVwOXMwSTJwYXRaVUJLWkhRWWVqc3M1aThFTzBlVE5xOG9UaFJ0WHItTEw5aVFuQ2JEVVpRUHhzckJyMXhXYmYxLWVZaXBIY0ZnU2gyTHZ2MzNPaEFYeC1PRkNtVEwtNkh3S3ZSeFZSdlNLMl9YaHVpTGVxSkZsUWViR2ZpWkVBNGNIeWd3czg3cm45Vy1jSWpnY0tidFYxRmh2STc0aGFyRFRuTFM4M3ZEMjB1dnRhdy1xamY4?oc=5","date":"2025-01-07","type":"regulatory","source":"BioPharma APAC","summary":"Norgine Submits Marketing Authorisation Application to EMA for Eflornithine in High-Risk Neuroblastoma - BioPharma APAC","headline":"Norgine Submits Marketing Authorisation Application to EMA for Eflornithine in High-Risk Neuroblastoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxOVldVNWQzM3ZBSklLOUtnRGRjelpIY1pXeGFFRWsyVDc2VnFRTFJvT01tekJKV0lMX1dNUlY2QTNYNHFSOUliektSell5Mzd3c3dJSExtNFQ3azVhQkt1QUJzM3hPVjNsX0RYekk5NUpXc1JCQjdnTUZjYzFiVkxUOVg1ZDJYd0NFOFRqLUhMb295SGRPdnp5RDU2eHFxakJnb2dmYm9iUDBCRFIyem5NWUxtdDl6UE9YMlhfSzdpWUdDMlZKbFpjVnd5dThacVhmZ1ZIdWhwTnhvd0dBd1p1THhmUDlMWW1SN05mcy1HQ1BnenVqTllqS283ZnZxZnl1NkI1ZF9tSVd2VFlhOXhSM1JfeUQwNVV5cXFzWU1NaGFQRTRPdW9zdWdGaGxkcEhZN09mR2xGWno?oc=5","date":"2025-01-06","type":"pipeline","source":"PR Newswire","summary":"Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma - PR Newswire","headline":"Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylorn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxNTVR0bnA4V05ISFZJM0tmUEVUX1ZIZDNuUnFhdHdPOVdTQkNsbEpkVUcxMElvVFNTMy1idHNiaEJxTGItdEthS1BQcTRmTWRhRl9aTFdZVUliVDJpeS1vSV9HSU1DTVRJLTBlSjJKSFF5ZDAzZXVKd3BrVDFuLW0ybVpJdVpVbUVrRk1KLUgwa0ZLZGFxZE1oZTdNeXhfUU9KdE0ya2xrMW1hWmYzcUZDRXNsY1QtaXNxTmR2SmwxMVJfTlJGdzNxNDFIUGJROE03UXgwTzNfeWtVTUJaeENtN2RYWC1WMDBCN0NKblQ3b1duTWFuUVUtS3lGb29odnM0ZU1Hb3MwVDU4NzVaYjBHbDBrZ1pSenNuQnJRM2s3YzViNkdBczhlVDRRdw?oc=5","date":"2024-04-15","type":"pipeline","source":"PR Newswire UK","summary":"Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma - PR Newswire UK","headline":"Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DF","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}